盐酸替罗非班在ST段抬高急性心肌梗死急诊PCI中的疗效和安全性观察

目的：通过随机对比分析,观察国产血小板膜糖蛋白Ⅱb/Ⅲa受体拮抗剂盐酸替罗非班在急性ST段抬高急性心肌梗死（STEMI）急诊经皮冠状动脉介入治疗（PCI）中的疗效和安全性观察。方法：将49例患者随机分为实验组和对照组,实验组在对照组给予阿司匹林、氯吡格雷的基础上提前应用盐酸替罗非班,比较两组的疗效和安全性。结果：与对照组相比,实验组术前IRA前向血流达到TIMI1级的比率高于对照组,其中达到TIMI3级的比率亦明显高于对照组。两组心血管事件发生率、出血事件与血小板减少症发生率无明显差异。结论：ST段抬高急性心肌梗死患者在急诊PCI术前应用盐酸替罗非班是安全有效的。

Tirofiban hydrochloride in ST-segment elevation acute myocardial infarction in the efficacy and safety of PCI observation

Objective： To observe the efficacy and safety of platelet membrane glycoprotein observation made Ⅱb/Ⅲa receptor antagonist tirofiban hydrochloride in patients with acute ST-segment elevation acute myocardial infarction （STEMI） percutaneous coronary intervention （PCI） through random analysis. Methods： 49 cases of patients were randomly divided into experimental group and control group, the experimental group were given aspirin, clopidogrel, based on early application of tirofiban hydrochloride, compared the efficacy and safety of the two groups. Results： Compared with the control group, the experimental group before the preoperative blood flow to TIMI 1 IRA level was higher than that of the control group, the rate in which the ratio had reached TIMI 3 was significantly higher than control group. There was no significant difference of cardiovascular events, bleeding events and thrombocytopenia between the two groups. Conclusion： ST-segment elevation acute myocardial infarction patients before surgery in the emergency PCI tirofiban hydrochloride is safe and effective.